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A Systematic Review of Biological Mechanisms of Fatigue in Chronic Illness
Abstract
Fatigue, a commonly reported symptom, is defined as an overwhelming, debilitating, and sustained sense
of exhaustion that decreases the ability to function and carry out daily activities. To date, cancer
researchers have been in the forefront in investigating the possible biological mechanisms of fatigue,
identifying inflammation, dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis, and activation
of the autonomic nervous system. The purpose of this systematic review is to describe fatigue and what
is known about the biological mechanisms described in cancer in five chronic, noninfectious illnesses:
heart failure, multiple sclerosis, chronic kidney disease, rheumatoid arthritis, and chronic obstructive
pulmonary disease. We searched PubMed and EMBASE using fatigue as a major Medical subject
headings (MeSH) heading with each individual disease added as a search term followed by each
biological mechanism. We included only primary research articles published in English between 1996 and
2016 describing studies conducted in adult humans. We identified 26 relevant articles. While there is
some evidence that the biological mechanisms causing fatigue in cancer are also associated with fatigue
in other chronic illnesses, more research is needed to explore inflammation, the HPA axis, and the
autonomic nervous system, and other mechanisms in relation to fatigue in a variety of chronic illnesses.
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A Systematic Review of Biological Mechanisms of Fatigue in Chronic Illness
Abstract
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Fatigue is a commonly reported symptom defined as an overwhelming, debilitating, and sustained sense of
exhaustion that is unpleasant and decreases the ability to function and carry out daily activities. To date, cancer researchers
have been in the forefront in investigating the possible biological mechanisms of fatigue. Investigators of cancer related
fatigue have identified the biological mechanisms of inflammation, dysregulation of the hypothalamic-pituitary-adrenal (HPA)
axis, and activation of the autonomic nervous system. The purpose of this systematic review is to describe fatigue and what
is known about these biological mechanisms of fatigue in five chronic, non-infectious illnesses: heart failure, multiple
sclerosis, chronic kidney disease, rheumatoid arthritis, and chronic obstructive pulmonary disease. We searched PubMed
and EMBASE using “fatigue” as a major MESH heading with each individual disease added as a search term followed by
each biological mechanism. We included only primary research articles published between 1996 and 2016 that were
conducted in adult humans and written in English. We identified 26 relevant articles. While there is some evidence that the
biological mechanisms causing fatigue in cancer are also associated with fatigue in other chronic illnesses, more research is
greatly needed to explore inflammation, the HPA axis, and the autonomic nervous system and other mechanisms in relation
to fatigue in a variety of chronic illnesses.
Key words: fatigue, inflammation, hypothalamic-pituitary-adrenal axis, autonomic nervous system, heart failure, multiple
sclerosis, chronic kidney disease, rheumatoid arthritis, chronic obstructive pulmonary disease.
Fatigue has been defined as an overwhelming, debilitating, and sustained sense of exhaustion that is unpleasant and
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decreases the ability to function and carry out daily activities (Cella et al., 2007). Fatigue is reported by up to 45% of the US
population and greatly reduces overall quality of life (Ricci, Chee, Lorandeau, & Berger, 2007). Fatigue that is chronic and
unresponsive to rest may be a sign of underlying pathology (Jorgensen, 2008) and chronic illness (Ricci et al., 2007). Much
of the research on fatigue has been conducted in cancer patients, but fatigue is also known to occur commonly in persons
with heart failure, multiple sclerosis, chronic kidney disease, rheumatoid arthritis, and chronic obstructive pulmonary disease
(Junghaenel, Christodoulou, Lai, & Stone, 2011). Fatigue may also be a prodromal symptom for acute myocardial infarction
(McSweeney et al., 2003) and major depression (Fava, Grandi, Canestrari, & Molnar, 1990). It may be a different entity in
healthy and disease states but this is not fully understood at this point. In chronic illness, fatigue may be a protective factor
signaling the body to rest.
Despite the prevalence of fatigue and its negative impact on the human experience, research exploring mechanisms
of fatigue in different disease states is limited. Investigators of cancer have led the way in describing and exploring the
underlying mechanisms of fatigue. As described below, cancer-related fatigue is thought to be caused by inflammation,
dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, and/or activation of the autonomic nervous system (Bower,
2014; Ryan et al., 2007; Saligan et al., 2015). Although many studies investigating biological mechanisms of fatigue have
focused on only one possible mechanism (e.g. inflammation), these biological pathways can influence each other and
activate other systems (Figure 1). For example, activation of the sympathetic nervous system, a branch of the autonomic
nervous system, can produce a proinflammatory response (Pongratz & Straub, 2014). Perhaps it is the complexity of these
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issues that has resulted in so little research in the area.
The purpose of this systematic review is to describe fatigue and what is known about the biological mechanisms of
fatigue in five chronic, non-infectious illnesses: heart failure (HF), multiple sclerosis (MS), chronic kidney disease (CKD),
rheumatoid arthritis (RA), and chronic obstructive pulmonary disease (COPD).
Methods
With the support of a medical librarian we searched using PubMed and EMBASE using “fatigue” as a major MESH
heading with each individual disease (e.g. “heart failure”) added as a search term followed by each mechanism (e.g.
inflammation). We included only primary research articles from 1996-2016 that were conducted in adult humans and written
in English. The initial search resulted in 970 articles (Figure 2). After removing duplicates, 656 article titles and abstracts
were assessed for relevance. Thirty-eight full text articles were reviewed, with 12 more excluded because they did not
investigate fatigue in an illness of interest (i.e., HF, MS, CKD, RA or COPD) with discussion of one of three specific
mechanisms (i.e., inflammation, HPA axis, or autonomic nervous system). Electronic searches were supplemented by
manual searching of reference lists and reviews. This process produced another 2 articles on RA. Twenty-six articles fulfilled
the inclusion criteria and were independently reviewed by the four authors. All articles judged to be potentially relevant were
discussed by the group before including them in this systematic review.
Cancer-Related Fatigue
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Prior literature reviews have focused on possible biological mechanisms or etiologies of cancer-related fatigue
(Bower, 2014; Ryan et al., 2007; Saligan et al., 2015). Cancer-related fatigue is commonly reported in relation to cancer
treatments; however, fatigue may be present before treatment and may increase during therapy. Fatigue may limit the
receipt of optimal courses of treatment due to early discontinuation and fatigue may be a prognostic factor in cancer survival
(Bower, 2007). Research on possible biological mechanisms of cancer-related fatigue has been robust because such
understanding is believed to potentially lead to targeted interventions to improve fatigue and ultimately quality of life.
Mechanisms of fatigue in cancer
Possible biological mechanisms of cancer-related fatigue include inflammation, dysregulation of the HPA axis, and
activation of the autonomic nervous system (Bower, 2014; Saligan et al., 2015). Inflammation related to the release of
inflammatory cytokines such as interleukin (IL)-1 beta, IL-6 and tumor necrosis factor (TNF) alpha has been implicated in
cancer-related fatigue prior to treatment, during treatment and after treatment (Bower, 2014). Dysregulation in the HPA axis
has been implicated in cancer-related fatigue with alterations in cortisol levels (Saligan et al., 2015) or cytokine production
(Saligan et al., 2015) and resulting increased inflammation. In addition, activation of the autonomic nervous system with
increased sympathetic activity and reduced parasympathetic activity may contribute to cancer-related fatigue (Bower, 2014).
Inflammation. Inflammation is a component of immune function and patients with cancer have increased levels of
inflammatory markers (e.g. TNF alpha, IL-6) that are associated with fatigue levels (Ryan et al., 2007; Saligan et al., 2015).
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For example, prior to treatment, patients with acute myelogenous leukemia had elevated inflammatory markers, which were
associated with fatigue levels (Meyers, Albitar, & Estey, 2005). Similarly, patients with ovarian cancer had elevated levels of
IL-6 that were associated with fatigue prior to surgery (Lutgendorf et al., 2008).
Cancer treatments have also been found to increase fatigue and inflammation during treatment and after treatment
(Bower, 2014). During radiation treatment for breast or prostate cancer, fatigue was found to be associated with C reactive
protein (CRP) and IL-1 levels (Bower et al., 2009). A similar result was found in breast cancer patients undergoing
chemotherapy, with fatigue associated with IL-6 levels (Liu et al., 2012). Patients with advanced colorectal, esophageal and
non-small cell lung cancer who were receiving both radiation and chemotherapy had fatigue levels associated with increased
inflammation (IL-6) (Bower, 2014; Wang et al., 2010). After treatment for cancer, fatigue can persist for 5-10 years or even
longer (Bower et al., 2006). Both TNF receptor II (Bower et al., 2011) and CRP (Alexander, Minton, Andrews, & Stone, 2009)
levels have been associated with fatigue one month after the completion of treatment in patients with breast cancer.
HPA Axis. Dysregulation of the HPA axis may be a mechanism in cancer-related fatigue or may cause inflammation that
ultimately produces fatigue (Bower, 2014; Saligan et al., 2015). Anti-inflammatory properties may be affected by altering
glucocorticoid production by the HPA axis and by regulating HPA axis cytokine production (McEwen et al., 1997). Cortisol
levels were higher in breast cancer patients reporting fatigue compared to their counterparts without fatigue (Bower et al.,
2005). Cortisol levels were also higher and cortisol variability was reduced in patients with ovarian cancer reporting fatigue
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before cancer treatment (Weinrib et al., 2010).
Autonomic Nervous System. The autonomic nervous system, both the sympathetic and parasympathetic branches, is
thought to play a role in cancer-related fatigue (Bower, 2014; Ryan et al., 2007) because an increased sympathetic response
may increase inflammation. There may also be a vagal response from cancer treatments that induces “sickness behavior”
(Ryan et al., 2007). In patients with breast cancer, fatigue was associated with elevated levels of norepinephrine
(sympathetic response) and lower heart rate variability (parasympathetic response) (Fagundes et al., 2011).
Using cancer-related fatigue as the gold standard for comparison, the next sections explore five non-infectious
illnesses to describe fatigue and explore the similarity between mechanisms. Table 1 outlines the measures used to study
inflammation, the HPA axis and the autonomic nervous system for each disease. Table 2 includes the measures of fatigue
used in each study.
Fatigue of Heart Failure
Fatigue and dyspnea are the hallmark symptoms of chronic HF, but there is surprisingly little research on the fatigue
of HF. In a qualitative study, HF fatigue was described as having both bodily and mental aspects (Falk, Granger, Swedberg,
& Ekman, 2007). The bodily experience of fatigue was described by patients as a feeling of lacking strength and energy and
feeling sleepy. The mental aspects of fatigue were described as demoralization and intellectual deficiency. Restorative
activites (e.g., social interaction) alleviated fatigue in this small sample of patients with chronic HF.
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The fatigue of HF may reflect interacting peripheral and central factors (Witte & Clark, 2004). Peripheral or muscle
fatigue is typically described as a deficiency in peripheral blood flow and skeletal muscle function leading to exercise-induced
fatigue (Coats, 1998; Kränkel et al., 2003; Piepoli, Scott, Capucci, & Coats, 2001). Exercise training is proposed as the
appropriate treatment for peripheral fatigue. Others speak about peripheral fatigue as a contributor to central fatigue of HF
(Marzilli, 2014). The manner in which peripheral and central factors interact in HF needs further study, but for the purposes
of this review we focused on central fatigue. In HF, greater fatigue is associated with worse clinical outcomes (Perez-Moreno
et al., 2014). Smith and colleagues (Smith, Kupper, de Jonge, & Denollet, 2010) found that both severe exertional fatigue
and severe general fatigue significantly predicted an increased mortality rate.
Mechanisms of Fatigue of Heart Failure
Studies of mechanisms of fatigue in HF are limited and clearly more research is needed. Fatigue in HF has been
attributed to illness severity (Jasiukeviciene et al., 2008) chronic hyponatremia, (Rai, Whaley-Connell, McFarlane, & Sowers,
2006) sleep apnea (Köhnlein, Klante, Elliott, & Welte, 2001), and depression (Fink et al., 2012; Iasiukiavichene &
Vasiliauskas, 2006; Smith, Gidron, Kupper, Winter, & Denollet, 2009). Others discuss the fatigue of HF in terms of vital
exhaustion, a psychological state characterized by unusual fatigue and depression, which has been linked to elevated levels
of pro-inflammatory cytokines (Herrmann-Lingen et al., 2003).
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Inflammation. Several investigative teams have studied the link between fatigue of HF and inflammation. Fink and
colleagues found that fatigue was associated with HF severity as measured by the Seattle HF Model but cytokine levels
were not associated with fatigue (Fink et al., 2012). Two teams have proposed dietary treatments to reduce inflammation.
One team improved fatigue in HF patients by supplementing ubiquinol + L-carnitine to reduce pro-inflammatory cytokines
(Kumar et al., 2007). Another team is currently studying the influence of supplemental lycopene and omega-3 fatty acids on
fatigue in HF patients (Lennie et al., 2013). These nutritional approaches address components in the mitochondrial electron
transport chain pathway, a deficiency that is rare except in liver disease (Paradies, Paradies, Ruggiero, & Petrosillo, 2014).
Such dietary approaches to influencing the fatigue of HF represent a unique approach to a problem that is poorly
understood.
HPA Axis. Few investigators have studied the influence of the HPA axis on the fatigue of HF. In a study of coronary artery
disease patients (48 of 83 participants had HF), decreased thyroid hormone concentrations were independently associated
with higher levels of physical fatigue and lower morning cortisol levels were independently associated with higher levels of
mental fatigue (Bunevicius et al., 2012).
Autonomic Nervous System. The effect of the autonomic nervous system on the symptom of fatigue has not been studied
in HF.
Fatigue in Mulitple Sclerosis
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Fatigue is common in people with MS and is similar to fatigue reported by individuals with other chronic illnesses and
healthy individuals (Krupp, 2003). Fatigue of MS is disabling, as assessed by self-report and by performance-based
measures of motor and cognitive function. Motor fatigue is significantly greater in MS than healthy individuals (Djaldetti, Ziv,
Achiron, & Melamed, 1996). Memory and conceptual thinking are decreased in MS compared to healthy controls and both
decline over the time course of the disease (Krupp & Elkins, 2000). Fatigue is associated with psychological distress and
depressed mood along with neurological impairment; depressed mood influences the experience of fatigue in MS (Krupp,
LaRocca, Muir-Nash, & Steinberg, 1989). Patients who are distressed and depressed have higher levels of fatigue
(Kroencke, Lynch, & Denney, 2000); (Krupp et al., 2002). Fatigue is a common feature that is associated with unemployment
in patients with MS (Cadden & Arnett, 2015).
Mechanisms of Fatigue in MS
Few studies have investigated possible mechanisms of fatigue in MS, perhaps believing that fatigue is a physiological
adaptation to the pathology of MS (Krupp & Elkins, 2000). One possible explanation that may be unique to MS is
involvement of the central nervous system. In MS there may be changes in the premotor, limbic, basal ganglia or brainstem
area that decrease motivation or motor readiness resulting in fatigue (Krupp, 2003). Immune function, specifically
inflammatory cytokines (lriarte, Subirá, & de Castro, 2000), is implicated as a possible cause of fatigue in MS as are
alterations in the neuroendocrine system (Powell, Moss-Morris, Liossi, & Schlotz, 2015).

12

Inflammation. One MS study focused solely on inflammation. Markers of systemic inflammation were not associated with
self-report fatigue levels (Giovannoni, Thompson, Miller, & Thompson, 2001). Injection of interferon beta, a type of cytokine
therapy used in MS to balance pro-and anti-inflammatory agents in the brain, can reduce the rate of MS relapses. However,
4 hours after injection of interferon beta, patients reported higher fatigue scores that were associated with the percentage of
granulocytes relative to total leukocytes, suggesting an increased inflammatory response (Goebel et al., 2005). In another
study, increased CD8+ T cells and cortisol levels were associated with fatigue in MS suggesting a possible contribution of
both inflammation and HPA axis to fatigue (Gold et al., 2011). TNF alpha and interferon gamma were higher in patients with
MS who reported fatigue (Heesen et al., 2006).
HPA axis. Cortisol, a common marker of stress, regulates the immune system and energy metabolism. Fatigue is associated
with lower waking cortisol levels and larger awakening cortisol responses in MS (Powell et al., 2015). MS patients with
fatigue had higher levels of adrenocorticotropic hormone, a compound that can increase cortisol production and release,
than those who did not report fatigue.
Autonomic Nervous System. In one study, hand grip (one test of autonomic function) was associated with self-reported
fatigue scores (Merkelbach, Dillmann, Kölmel, Holz, & Müller, 2001). Increased vagal activity occurred in younger patients
with MS (less than 45 years old) who reported fatigue (Keselbrener et al., 2000).
Fatigue in Chronic Obstructive Pulmonary Disease
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Fatigue is common, often severe and disabling in COPD (Baltzan et al., 2011). Although dyspnea is the primary
symptom that interferes with patients’ lives, fatigue is the next most common symptom (Paddison, Effing, Quinn, & Frith,
2013). Dyspnea and fatigue scores are associated with impaired physical functioning (Woo, 2000) and reduced ability to
perform daily activites (Kapella, Larson, Patel, Covey, & Berry, 2006). Fatigue can increase COPD progression, negatively
affect health status and quality of life, and lead to disablity in these patients (Paddison et al., 2013);,(Baghai-Ravary et al.,
2009). Increasing fatigue levels also predict future hopitalizations (Paddison et al., 2013).
Mechanisms of Fatigue in COPD
Although fatigue is known to be common in COPD, there is little research on mechanisms of the fatigue. There may
be an association between fatigue and inflammation (Al-Shair et al., 2011) and between fatigue and the HPA axis in patients
with COPD (Schuetz et al., 2015). Research studying the association between fatigue and the autonomic nervous system is
needed in patients with COPD.
Inflammation. Only one study of patients with COPD assessed the association between fatigue and inflammatory markers
of TNF alpha, CRP and IL-6 (Al-Shair et al., 2011). Only higher levels of TNF alpha were associated with fatigue in patients
with COPD.
HPA axis. Only one study investigated the association between fatigue and adrenal function in COPD. These investigators
did not find an association between fatigue and cortisol levels (Schuetz et al., 2015).

14

Autonomic Nervous System. We did not find any studies investigating the association of the autonomic nervous system
and fatigue in COPD.
Fatigue in Chronic Kidney Disease
Fatigue is one of the most common symptoms reported by people living with chronic kidney disease (CKD), with an
average prevalence of 71% (Murtagh, Addington-Hall, & Higginson, 2007). Patients with CKD have described fatigue as a
constant lack of energy (A. E. Horigan, 2012) that investigators have attributed to both physical and mental domains. Fatigue
is especially prevalent in those with end-stage renal disease receiving hemodialysis (CKD5) (Caplin, Kumar, & Davenport,
2011; Jablonski, 2007; Weisbord et al., 2005). One study found that 14.7% of the patients with CKD5 had fatigue scores
higher than twice the standard deviation of the mean for healthy volunteers (Koyama et al., 2010). Fatigue in these patients
is associated with reduced quality of life, increased the risk of cardiovascular events, and reduced survival (Bossola, Vulpio,
& Tazza, 2011; A. Horigan, Rocchiccioli, & Trimm, 2012; A. E. Horigan, 2012; Koyama et al., 2010). Fatigue predicts
cardiovascular events in CKD5, independent of accepted risk factors of age, diabetes, malnutrition, and a history of
cardiovascular disease (Koyama et al., 2010).
Mechanisms of Fatigue in Chronic Kidney Disease
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Mechanisms of fatigue in chronic kidney disease are largely understudied. However, existing studies suggest that
inflammation and the autonomic nervous system may be associated with the fatigue of CKD (Bossola, Di Stasio, Giungi,
Rosa, & Tazza, 2015; Cruz, Mahnensmith, & Perazella, 1997; Fujii et al., 2013).
Inflammation. CKD is thought to be a pro-inflammatory state; however, little is known regarding the inflammatory pathways
involving fatigue. One study revealed that fatigue in CKD5 was significantly associated with increased levels of IL-6 (Bossola
et al., 2015). No other studies exploring inflammatory pathways in relation to the fatigue of CKD were found.
HPA Axis. No studies investigating the relationship between the HPA axis and fatigue in CKD were found.
Autonomic Nervous System. One study compared autonomic function in CKD5 to that of healthy people (Fujii et al., 2013;
Fukuda et al., 2008). In CKD5 patients there was a positive association between impaired autonomic function and fatigue.
Fatigue in Rheumatoid Arthritis
RA is an autoimmune disease characterized by joint pain, tenderness and inflammation. It is accompanied by several
factors impacting quality of life, including sleep disturbances, pain, depression, and fatigue (Jump, Fifield, Tennen, Reisine,
& Giuliano, 2004; Pollard, Choy, Gonzalez, Khoshaba, & Scott, 2006). Fatigue has been reported in about 80% of persons
with RA and was rated as severe by 50% (Pollard et al., 2006). Individuals with RA describe fatigue as a loss of physical and
mental energy, or weariness and lack of motivation, that is overwhelming (Hewlett et al., 2005). While patients consider

16

management of their fatigue a treatment priority, it is infrequently addressed by health care providers and rarely considered a
primary outcome in RA research (Hewlett et al., 2005; Hewlett, Nicklin, & Treharne, 2008).
Mechanisms of Fatigue in Rheumatoid Arthritis
Several treatments targeting improvement in RA disease activity have also reduced fatigue. For example, fatigue was
reduced when pharmacologic agents were given to reduce inflammation caused by disease activity (Almeida et al., 2016;
Chauffier, Salliot, Berenbaum, & Sellam, 2012), when physical activity was increased to limit physical deconditioning (Cramp
et al., 2013), and when psychosocial interventions were used to improve coping strategies and promote behavior change
(Cramp et al., 2013). Because these studies were not designed to focus on fatigue, no effort was given to elucidating the
mechanisms underlying RA related fatigue. The success of these varied approaches in reducing RA related fatigue, albeit
limited, suggests that multiple mechanisms lead to RA related fatigue (Cramp et al., 2013).
Inflammation. The inflammatory activity that characterizes RA as measured by swollen/tender joint counts, erythrocyte
sedimentation rates (ESR), CRP, and the Disease Activity Score 28 (a composite score), has an inconsistent relationship
with RA related reports of fatigue (Bergman et al., 2009; van Hoogmoed, Fransen, Bleijenberg, & van Riel, 2010). Patients
reporting either the least or the greatest fatigue have minimal evidence of inflammation (low swollen joint counts and low
CRP), whereas patients reporting moderate fatigue have high swollen joint counts and CRP (Lee et al., 2014). Few
measures of inflammation have been associated with RA-related fatigue in cross-sectional (Bergman et al., 2009; van
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Hoogmoed et al., 2010) or longitudinal studies (Druce, Jones, Macfarlane, Verstappen, & Basu, 2015; Feldthusen, GrimbyEkman, Forsblad-d'Elia, Jacobsson, & Mannerkorpi, 2016; Repping-Wuts, Fransen, van Achterberg, Bleijenberg, & van Riel,
2007; Treharne et al., 2008). RA related fatigue has a mixed association with IL-6 in chronically stressed patients. In-vivo
plasma levels of IL-6 have not been associated with RA-related fatigue, but increased in-vitro stimulated cellular production
of IL-6 and reduced glucocorticoid inhibition of IL-6 have been associated with fatigue (Davis et al., 2008).
Capitalizing on the use of pharmacological interventions for RA that reduce joint inflammation and inhibit proinflammatory cytokines, several investigative teams sought to determine whether fatigue was reduced following
commencement of these treatments. After beginning anti-TNF treatment, 70% of patients who were non-responsive to
disease modifying anti-rheumatoid drugs reported reduced fatigue levels; effects were sustained in 80% of participants one
year later (Druce, Jones, Macfarlane, & Basu, 2015b). Responders were more likely to be non-hypertensive, non-depressed,
and non-steroid using seropositive females reporting good mental health and low disability levels (Druce, Jones, et al.,
2015b). Changes in fatigue were not directly related to inflammation or disease activity but were related to reductions in pain,
mental health, depression, and disability (Druce, Jones, Macfarlane, & Basu, 2015a). Evidence that RA related fatigue
continues to be reported even after disease remission confounds our understanding of the possible role of inflammation in
RA related fatigue (Druce, Bhattacharya, Jones, Macfarlane, & Basu, 2016). Collectively, this limited evidence is
inconclusive regarding a precise role for inflammation in RA related fatigue.
HPA Axis. No studies investigating the relationship between the HPA axis and fatigue in RA were found.
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Autonomic Nervous System. No studies investigating the relationship between the autonomic nervous system and fatigue
in RA were found.
Discussion
While investigators of cancer lead the way in defining possible mechanisms of fatigue, little research has been done
investigating possible biological mechanisms of the common symptom of fatigue in other chronic illnesses. In this review we
synthesized the current state of the literature describing inflammation, HPA axis and the autonomic nervous system as
possible mechanisms of fatigue in patients with HF, MS, COPD, CKD and RA—common chronic conditions associated with
persistent and disabling fatigue.
We found studies investigating the association between fatigue and inflammation in HF, MS, COPD, CKD and RA.
However, there were conflicting reports in MS and RA where increased inflammation was not consistently associated with
elevated levels of inflammatory markers. Possible reasons for this discrepancy could be related to the procurement and
processing of the blood samples, disease severity, small sample sizes or other treatment effects. In addition, common
inflammatory markers tested were IL-6, TNF alpha and CRP; perhaps there are other pro-inflammatory and antiinflammatory markers associated with fatigue that have not been tested as yet.
Studies investigating fatigue and the HPA axis were only found in patients with HF, MS and COPD. Cortisol is a
commonly used measure of the HPA axis. Cortisol levels were associated with mental fatigue in HF, fatigue levels in MS but
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not in patients with COPD. However, in several illnesses these were only single studies, so few conclusions can be drawn.
There may be other mechanisms that are unique to specific disease processes.
The autonomic nervous system and fatigue were studied in patients with HF, MS and CKD. The autonomic nervous
system was implicated in peripheral fatigue in patients with HF; notably, only HF distinguished between peripheral or central
fatigue. Impaired autonomic function was associated with fatigue in patients with MS and CKD. Typically, a battery of tests is
used to evoke both sympathetic and parasympathetic responses. There was variability in the measurement of autonomic
function across the HF, MS, and CKD studies. Without consistent measurements across disease states it is difficult to
discern if these mechanisms of fatigue are the same among the diseases.
There are few studies testing the HPA axis or the autonomic nervous system as mechanisms for fatigue in the chronic
diseases we examined. Even for studies of inflammation and fatigue, the methods used to collect specimens varied
significantly (e.g. time of day when samples were collected). There is a circadian effect for inflammatory markers, the HPA
axis, and the autonomic nervous system (Kalsbeek et al., 2012; Li et al., 2011). If this circadian effect was not accounted for
in the studies, results may be suspect.
Another limitation is that self-reported fatigue was measured by a variety of different instruments. Some of the fatigue
measures were subscales of more general instruments. For example, the Profile of Mood States measures vigor and
depression along with fatigue (Curran, Andrykowski, & Studts, 1995). As investigators continue to study fatigue, a more
uniform measure such as the Patient-Reported Outcomes Measurement Information System (PROMIS ®) fatigue measure
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would allow for comparisons across studies and diseases. Finally, there is the possibility that negative studies were not
published. Absence of these findings impact our conclusions of possible mechanisms of fatigue.
Other factors that may contribute to fatigue in chronic illnesses include anemia, depression, sleep disorders (Ryan et
al., 2007), and genetic risk factors (Bower, 2014) (e.g. IL6 single nucleotide polymorphisms). These factors may be
mechanisms of fatigue and need to be explored in future studies.
Conclusions and Future Directions
While there is evidence of some underlying biological mechanisms of fatigue in cancer and the other chronic illnesses
we explored, there are still gaps and areas of limited knowledge. Inflammation, the HPA axis, and the autonomic nervous
system may interact to cause or accentuate fatigue, but more research is greatly needed to explore these mechanisms and
others. Consistent measurements of self-reported fatigue and biological mechanisms are needed in order to compare and
contrast different disease states. Because fatigue is a commonly reported symptom that can be debilitating, understanding
biological mechanisms is essential in order to test targeted interventions.
The National Institutes of Health/National Institute of Nursing Research (NINR) recommends common data elements
for measuring fatigue https://cde.nlm.nih.gov/formView?tinyId=QktmQ9BqM. At the time of this writing, NINR is seeking input
from stakeholders regarding common data elements for measuring biomarkers such as cytokines (IL-1beta, IL-6, IL-10) for
inflammation and free cortisol for HPA axis. Using standardized measurements of both patient-reported outcomes and
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biomarkers should be considered when designing future research in order to facilitate comparisons across disease states
and patient populations.

Table 1. Inflammation, HPA axis, and Autonomic Nervous System Measures
used in Chronic, Non-infectious Diseases

Inflammation

Cancer

Heart Failure

Multiple
Sclerosis

COPD

TNF-alpha:
(Saligan LN
et al., 2015;
Ryan JL ,
et al., 2007;
Fink et al.
2012)

TNF-alpha:
(Fink et al.,
2012; Kumar et
al., 2007;
Lennie et al.,
2013)

Urinary
neopterin
excretion:
(Giovannoni,
2001)

TNFalpha: (AlShair,
2011)

IL-6:
(Saligan
LN et al.,
2015;
Ryan JL ,
et al.,
2007;
Bower,
2014;
Lutgendorf
, 2008;

sTNFR1 and
sTNFR2:
(Lennie et al.,
2013)

CRP:
(Giovannoni,
2001)

Soluble
intercellular
adhesion
IL-6: (Fink et al., molecule-1:
2012; Kumar et (Giovannoni,
al., 2007)
2001)
IL-10: (Fink et
al., 2012;

IFN γ:
(Goebel,

IL-6: (AlShair,
2011)
CRP: (AlShair,
2011)

Chronic
Kidney
Disease
IL-6:
(Bassola et
al., 2015)

Rheumatoid
Arthritis
IL-6: (Davis et
al., 2008)
CRP: (Lee at
al., 2014;
Druce, Jones,
McFarlane,
Basu, 2015a)
Erythrocyte
sedimentation
rate: (Treharne
et al., 2008;
Druce, Jones,
McFarlane,
Basu, 2015a)
Disease
Activity Score
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Liu, 2012;
Wang
2010; Fink
et al.,
2012)

Kumar et al.,
2007; Lennie et
al. 2013F)
CRP: (Fink et
al., 2012)

IL-1 beta
(Bower,
2009;
Alexander
, 2009)

2005)

in 28 joints
(DAS28):
(Bergman et
al., 2009;
Druce, Jones,
Macfarlane,
Verstappen,
Basu, 2015;
Druce, Jones,
Macfarlane,
Basu, 2015a;
Druce, Jones,
Macfarlane &
Basu, 2015b;
Druce,
Bhattacharya,
Jones,
Macfarlane,
Basu 2016;
Feldthusen et
al., 2016;
Repping-Wuts
et al., 2007;
van Hoogmoed
et al., 2010)

TNF-alpha:
(Goebel,
2005)
IL-10:
(Goebel,
2005)
CD8+ T cells:
(Gold, 2011)

CRP:
(Bower,
2009;
Alexander
, 2009)
Fink et al.,
2012
TNF
receptor
II: (Bower
, 2011)

HPA axis

Autonomic
Nervous
System

Cortisol:
(Bower,
2005;
Weinrib,
2010)
Norepinephrine:
(Fagunde
s, 2011)

Cortisol:
(Bunevicius et
al., 2012)

Cortisol:
(Gold, 2011,
Powell, 2015)

Battery of
tests:
(postural
changes,
pressure

Cortisol:
(Schuetz,
2015)

Heart Rate
Variability:
(Fujii et al.,
2013)
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Heart rate
variability:
(Fagunde
s, 2011)

tests, the
Valsalva
maneuver,
deep
breathing and
hyperventilati
on):
(Merkelbach,
2001)
Fluctuations
in HR, BP,
blood flow
during supine
and standing:
(Keselbrener,
2000)

HR=heart rate, BP=blood pressure, TNF=tumor necrosis factor, IL=interleukin, CRP= C reactive
protein, sTNFR =soluble tumor necrosis factor receptors, IFN γ= interferon gamma, CD8= cluster
of differentiation 8
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Table 2. Measures Used in the Studies of Fatigue in Chronic, Noninfectious Diseases
Disease

Fatigue Measurement Used

Heart Failure

Profile of Mood States
Visual analog scale
Memorial Symptom Assessment Scale—
Heart Failure
Multidimensional Fatigue Inventory (MFI20) and Dutch Exertion Fatigue Scale and
Standardized cardiopulmonary exercise
testing
Fatigue Scale

Multiple
Sclerosis

Fatigue Questionnaire Scale
Krupp’s Fatigue Severity Scale
Profile of Mood States
Modified Fatigue Impact Scale
Fatigue Severity Scale
Modified Fatigue Impact Scale
Revised Clinical Interview Schedule
Fatigue Severity Scale

COPD
Chronic
Kidney
Disease

Chronic Fatigue Scale
Fatigue Severity Scale
Manchester COPD Fatigue Scale
Modified Performance Score for COPD
Italian version of the Short Form (Short
form [SF]-36®) vitality scale

Kuratsume and Yumaguti “New Fatigue
Scale”

Articles cited in this
review
Fink et al, 2012
Kumar 2007
Lennie, et al, 2013
Bunevicius, et al, 2012

Powell, Moss-Morries,
Liosssi, 2015
Giovannoni, Thompson,
Miller, Thompson, 2001
Goebel et al. 2005

Gold et al. 2011
Heesen et al. 2006
Merkelbach, Dillmann,
Kolmel, Holz, Muller, 2001
Keselbrener et al. 2000
Al-shair et al. 2011
Schuetz et al. 2015

Bossola et al., 2015

Fuji et al., 2013; Fukada
et al., 2008
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Rheumatoid
Arthritis

SF-36 vitality scale

Multidimensional Health Assessment
Questionnaire (MDHAQ)
Visual Analog Scale (unspecified)
Visual Analog Scale (0-100 mm)

Bristol Rheumatoid Arthritis Fatigue
Multidimensional Questionnaire
Numerical Rating Scale
Fatigue severity subscale (Checklist
Individual Strength (CIS)-fatigue) of the
CIS (CIS20r)

Druce, Jones, McFarlane,
Basu, 2015a; Druce,
Jones, McFarlane, Basu,
2015b, Druce et al., 2016
Lee et al., 2014
Bergman et al., 2009
Druce, Jones, Macfarlane,
Verstappen, Basu, 2015;
Treharne et al., 2008
Feldthusen et al., 2016
Davis et al., 2008
Van Hoogmoed et al.,
2010; Repping-Wuts et
al., 2007
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Chronic Disease

Inflammation

Autonomic Nervous System

HPA Axis

Fatigue

Cognitive behavioral factors
(anxiety, depression,
cognitive impairment, sleep
quality, etc.)

Impaired physical
function and activity

Altered energy
balance

Patient Factors
(age, gender,
comorbid
conditions, etc.)

Figure 1. Chronic illnesses have underlying biological changes (inflammation, autonomic nervous system activation, HPA axis
dysregulation) that appear to be associated with fatigue. The biological changes can be influenced by patient characteristics and
modifiable factors. The cascade of events illustrated in this figure can impact cognitive behavioral factors, impair physical function,
activity, and energy balance.
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